Table 2.
Study characteristics
| Study | Country | Design | Brand of stents | n (ARS, SS) | Age (ARS, SS) | Male / Female; ARS / SS | Pre-Dysphagia score (ARS / SS) | Follow-up (mo) | Use of PPI (ARS / SS) | Preemptive dilation of stent (ARS/ SS) |
| Coron et al[10], 2016 | France | RCT, multicenter | Dostent | 20 | 68.9 | 16/4 | 2.75 (0-4) | 6 | NO | YES |
| Choostent | 18 | 74 | 15/3 | 2.65 (0-4) | 6 | YES | YES | |||
| Kaduthodil et al[11], 2011 | United Kingdom | RCT, single center | NR | 27 | NR | NR | NR | NR | NR | NR |
| NR | 23 | NR | NR | NR | NR | |||||
| Blomberg et al[12], 2010 | Sweden | RCT, multicenter | Z stent- Dua- valve | 28 | 74 | 21/7 | 62 (0-100) | 3 | NR | YES |
| Z-stent | 37 | 74 | 23/14 | 61 (0-100) | 3 | NR | YES | |||
| Sabharwal et al[13], 2008 | United Kingdom | RCT, single center | FerX- Ella – valve / | 24 | 71.3 | 15/7 | 2.73 (0-5) | 3 | NO | NR |
| Ultraflex | 26 | 66.3 | 21/5 | 2.54 (0-5) | 3 | YES | NR | |||
| Power et al[14], 2007 | Ireland | RCT, single center | Hanaro stent- valve | 24 | 68.4 | 14/10 | NR | 2 | NR | NR |
| Ultraflex | 25 | 73.9 | 17/8 | NR | 2 | NR | NR | |||
| Wenger et al[15], 2006 | Sweden | RCT, multicenter | Z stent-Dua | 19 | 75 | 13/6 | 63 ± 28 | 6 | NR | NR |
| Z-stent | 25 | 73 | 13/9 | 56 ± 31 | 6 | NR | NR | |||
| Shim et al[16], 2005 | South Korea | RCT, single center | Dostent | 12 | 65.3 | 12/0 | 2.83 ± - 0.85 | 1 | NO | YES |
| Covered metal | 12 | 62.7 | 11/1 | 3.25 ± 0.4 | 1 | NO | YES | |||
| Homs et al[6], 2004 | the Netherland | RCT, single center | FerX-Ella –valve / | 15 | 69 | 12/3 | 3 (0-5) | 6 | NR | NR |
| Fer x -Ella | 15 | 69 | 12/3 | 3 (0-5) | NR | NR |
RCT: Randomized controlled trials; SS: Standard stent; ARS: Anti-reflux esophageal stent; PPT: Proton pump inhibitors.